## Sadaf Ghaem-Maghami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5922168/publications.pdf

Version: 2024-02-01

84 papers

3,627 citations

32 h-index 58 g-index

88 all docs 88 docs citations

88 times ranked 5600 citing authors

#	Article	IF	CITATIONS
1	Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene <i>FOXO1</i> in Endometrial Cancer. Cancer Research, 2010, 70, 367-377.	0.4	308
2	Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncology, The, 2017, 18, 1665-1679.	5.1	207
3	Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncology, The, 2007, 8, 985-993.	5.1	193
4	Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Human Reproduction Update, 2014, 20, 449-462.	5.2	163
5	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	1.1	153
6	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 2021, 385, 2123-2131.	13.9	144
7	Ovarian Cancer Immunotherapy Using PDâ€L1 siRNA Targeted Delivery from Folic Acidâ€Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing. Advanced Healthcare Materials, 2015, 4, 1180-1189.	3.9	140
8	The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Research, 2016, 44, 1227-1246.	6.5	120
9	The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS). British Journal of Cancer, 2018, 118, 1349-1358.	2.9	115
10	Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20 Journal of Clinical Oncology, 2017, 35, 5501-5501.	0.8	114
11	Endometrial cancer. BMJ: British Medical Journal, 2011, 343, d3954-d3954.	2.4	107
12	Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?. Journal of Immunology, 2013, 191, 4589-4598.	0.4	105
13	Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20 Journal of Clinical Oncology, 2020, 38, 6000-6000.	0.8	105
14	Hydrophobic modification of low molecular weight polyethylenimine for improved gene transfection. Biomaterials, 2013, 34, 7971-7979.	5.7	96
15	Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunology, Immunotherapy, 2014, 63, 215-224.	2.0	96
16	A study of symptoms described by ovarian cancer survivors. Gynecologic Oncology, 2012, 125, 59-64.	0.6	77
17	Epithelial ovarian carcinoma diagnosis by desorption electrospray ionization mass spectrometry imaging. Scientific Reports, 2016, 6, 39219.	1.6	67
18	Dynamic Spectral Imaging: Improving Colposcopy. Clinical Cancer Research, 2009, 15, 1814-1820.	3.2	61

#	Article	IF	CITATIONS
19	Targeting of Aberrant $\hat{l}\pm v\hat{l}^2$ 6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Molecular Therapy, 2017, 25, 259-273.	3.7	61
20	The intelligent knife (iKnife) and its intraoperative diagnostic advantage for the treatment of cervical disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7338-7346.	3.3	59
21	A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology, 2013, 130, 140-146.	0.6	58
22	Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer. Clinical Cancer Research, 2017, 23, 3453-3460.	3.2	52
23	Predicting successful vaginal birth after Cesarean section using a model based on Cesarean scar features examined by transvaginal sonography. Ultrasound in Obstetrics and Gynecology, 2013, 41, 672-678.	0.9	49
24	Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin. Journal of Immunology, 2013, 191, 2437-2445.	0.4	49
25	Epigenetic Regulation of the Homeobox Gene <i>MSX1</i> Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Clinical Cancer Research, 2016, 22, 3097-3104.	3.2	45
26	Changes in Cesarean section scar dimensions during pregnancy: a prospective longitudinal study. Ultrasound in Obstetrics and Gynecology, 2013, 41, 556-562.	0.9	44
27	Adoptive Immunotherapy of Epithelial Ovarian Cancer with Vγ9Vδ2 T Cells, Potentiated by Liposomal Alendronic Acid. Journal of Immunology, 2014, 193, 5557-5566.	0.4	43
28	Psychological Issues Associated With Absolute Uterine Factor Infertility and Attitudes of Patients Toward Uterine Transplantation. Progress in Transplantation, 2016, 26, 28-39.	0.4	41
29	Determinants of success in treating cervical intraepithelial neoplasia. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 679-684.	1.1	40
30	Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 843-849.	1.1	38
31	Novel Hydroxysteroid $(17\hat{l}^2)$ Dehydrogenase 1 Inhibitors Reverse Estrogen-Induced Endometrial Hyperplasia in Transgenic Mice. American Journal of Pathology, 2010, 176, 1443-1451.	1.9	37
32	Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis. Cancer Research, 2018, 78, 1383-1391.	0.4	35
33	Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2018, 67, 1753-1765.	2.0	26
34	Achieving an early pregnancy following allogeneic uterine transplantation in a rabbit model. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 185, 164-169.	0.5	25
35	Perceptions and Motivations for Uterus Transplant in Transgender Women. JAMA Network Open, 2021, 4, e2034561.	2.8	25
36	Uterine allotransplantation in a rabbit model using aorto-caval anastomosis: a long-term viability study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 182, 185-193.	0.5	24

#	Article	IF	Citations
37	FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL. Molecular Cancer Research, 2015, 13, 1578-1590.	1.5	24
38	Multispectral imaging of organ viability during uterine transplantation surgery in rabbits and sheep. Journal of Biomedical Optics, 2016, 21, 106006.	1.4	23
39	Uterine Transplantation: Review of Livebirths and Reproductive Implications. Transplantation, 2021, 105, 1695-1707.	0.5	23
40	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. British Journal of Cancer, 2017, 116, 1287-1293.	2.9	22
41	Test of longâ€term uterine survival after allogeneic transplantation in rabbits. Journal of Obstetrics and Gynaecology Research, 2014, 40, 754-762.	0.6	20
42	Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection: a meta-analysis of 4450 patients. Thorax, 2012, 67, 526-532.	2.7	19
43	Survey of Perceptions of Health Care Professionals in the United Kingdom toward Uterine Transplant. Progress in Transplantation, 2015, 25, 56-63.	0.4	19
44	Achieving uterine autoâ€transplantation in a sheep model using iliac vessel anastomosis: a shortâ€term viability study. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 245-252.	1.3	19
45	Fertility treatment and cancersâ€"the eternal conundrum: a systematic review and meta-analysis. Human Reproduction, 2021, 36, 1093-1107.	0.4	19
46	A Study to Evaluate the Cause of Bone Demineralization in Gynecological Cancer Survivors. Oncologist, 2013, 18, 423-429.	1.9	18
47	Longâ€ŧerm compliance with followâ€up after treatment for cervical intraâ€epithelial neoplasia. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1103-1108.	1.3	17
48	Does fertility treatment increase the risk of uterine cancer? A meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 195, 52-60.	0.5	17
49	Management of stage la1 squamous cervical cancer and the importance of excision margins: a retrospective study of long-term outcome after 25 years of follow-up. American Journal of Obstetrics and Gynecology, 2014, 211, 625.e1-625.e6.	0.7	15
50	The DNA Methylomes of Serous Borderline Tumors Reveal Subgroups With Malignant- or Benign-Like Profiles. American Journal of Pathology, 2013, 182, 668-677.	1.9	13
51	Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. The Cochrane Library, 2017, 1, CD009836.	1.5	13
52	Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. Clinical Cancer Research, 2021, 27, 6457-6466.	3.2	11
53	COVIDâ€19 and the impact on gynecologic cancer care. International Journal of Gynecology and Obstetrics, 2021, 155, 94-101.	1.0	11
54	Molecular Characteristics and Risk Factors in Endometrial Cancer. International Journal of Gynecological Cancer, 2010, 20, 1207-1216.	1.2	10

#	Article	IF	Citations
55	Immunology of Uterine Transplantation: A Review. Reproductive Sciences, 2012, 19, 123-134.	1.1	10
56	The relationship between infertility treatment and cancer including gynaecological cancers. The Obstetrician and Gynaecologist, 2013, 15, 177-183.	0.2	10
57	Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1391-1401.	2.0	10
58	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. , 2021, 9, e001519.		10
59	A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB Journal, 2012, 26, 324-333.	0.2	9
60	Uterus transplantation in the human: a complex surgical, medical and ethical challenge. Human Reproduction, 2013, 28, 292-293.	0.4	9
61	The application of metabolomics in ovarian cancer management: a systematic review. International Journal of Gynecological Cancer, 2021, 31, 754-774.	1.2	9
62	Analysis of worldwide surgical outcomes in COVID-19-infected patients: a gynecological oncology perspective. Future Science OA, 2020, 6, FS0629.	0.9	8
63	Radiolabelling an <sup>18</sup> F biologic <i>via</i> facile IEDDA "click―chemistry on the GE FASTLabâ,,¢ platform. Reaction Chemistry and Engineering, 2021, 6, 1070-1078.	1.9	8
64	NY-ESO-1 expression in DCIS: A new predictor of good prognosis. Oncoscience, 2017, 4, 33-40.	0.9	7
65	Conservative management of uterine adenosarcoma: lessons learned from 20Âyears of follow-up. Archives of Gynecology and Obstetrics, 2019, 300, 1383-1389.	0.8	6
66	Anxiety and stress in women with suspected endometrial cancer: Survey and paired observational study. Psycho-Oncology, 2021, 30, 1393-1400.	1.0	6
67	A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer. European Journal of Gynaecological Oncology (discontinued), 2021, 42, 662.	0.3	5
68	Multispectral imaging of organ viability during uterine transplantation surgery. Proceedings of SPIE, 2014, , .	0.8	4
69	Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?. Current Cancer Drug Targets, 2017, 18, 5-15.	0.8	4
70	Uterine Transplantation Using Living Donation: A Cross-sectional Study Assessing Perceptions, Acceptability, and Suitability. Transplantation Direct, 2021, 7, e673.	0.8	4
71	Genetic polymorphisms of matrix metalloproteinases $1\hat{a}\in$ 3 and their inhibitor are not associated with premature labor. Future Science OA, 2018, 4, FSO332.	0.9	3
72	Registration and analysis of multispectral images acquired during uterine transplantation surgery. , 2012, , .		2

#	Article	IF	CITATIONS
<b>7</b> 3	Pregnancy following allogeneic uterine transplantation in a rabbit model. Fertility and Sterility, 2012, 98, S123-S124.	0.5	2
74	Metastatic low-grade fibromyxoid sarcoma of the broad ligament: A case report and literature review. Journal of Obstetrics and Gynaecology, 2016, 36, 852-854.	0.4	2
75	Use of biomedical photonics in gynecological surgery: a uterine transplantation model. Future Science OA, 2018, 4, FSO286.	0.9	2
76	Use of Laser Speckle Contrast Analysis during pelvic surgery in a uterine transplantation model. Future Science OA, 2018, 4, FSO324.	0.9	2
77	Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies. British Journal of Cancer, 2020, 123, 1471-1473.	2.9	2
78	Endometrial autotransplantation in rabbits: Potential for fertility restoration in severe Asherman's syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 248, 14-23.	0.5	2
79	Characterising ovarian cancer morphology and response to chemotherapy using fluorescence confocal endomicroscopy. , 2010, , .		1
80	Standardized Approach for Imaging and Measuring Cesarean Section Scars Using Ultrasonography. Obstetrical and Gynecological Survey, 2012, 67, 404-405.	0.2	0
81	Fertility Treatment and Cancers—The Eternal Conundrum: A Systematic Review and Meta-analysis. Obstetrical and Gynecological Survey, 2021, 76, 343-344.	0.2	O
82	Abstract B129: Chimeric antigen receptor T-cells targeting the $\hat{l}\pm\nu\hat{l}^26$ integrin demonstrate potent antitumor activity in multiple solid tumors. , 2016, , .	_	0
83	Abstract 4567: Immunomodulatory action of SGI-110 and combination with $\hat{l}^3\hat{l}'T$ cell immunotherapy in ovarian cancer. , 2018, , .		O
84	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. Obstetrical and Gynecological Survey, 2022, 77, 216-218.	0.2	O